l*******s
发帖数: 12 | 1 Jiangsu Hengrui Medicine （恒瑞医药） is a leading innovative pharmaceutical
company in China with annual sales of 5.5 billion Chinese Yuan in 2012 and
is poised to continue its growth in coming years. Under the leadership of
successful and experienced scientists and drug discovery veterans returning
from US/Europe, its R&D force now has over 800 scientists and has developed
the most robust innovative drug discovery pipeline in Chinese pharmaceutical
industry.
Hengrui’s R&D engine, Shanghai Hengrui （上... 阅读全帖 |
|
l*******s
发帖数: 12 | 2 Jiangsu Hengrui Medicine （恒瑞医药） is a leading innovative pharmaceutical
company in China with annual sales of 5.5 billion Chinese Yuan in 2012 and
is poised to continue its growth in coming years. Under the leadership of
successful and experienced scientists and drug discovery veterans returning
from US/Europe, its R&D force now has over 800 scientists and has developed
the most robust innovative drug discovery pipeline in Chinese pharmaceutical
industry.
Hengrui’s R&D engine, Shanghai Hengrui （上... 阅读全帖 |
|
发帖数: 1 | 3 The Molecular Informatics department performs molecular design and
informatics support to the small molecules and biologics drug discovery
programs within the R & D center at Shanghai Hengrui Pharmaceutical Inc.
Opening position
Scientist/Senior scientist:
We have an open position for small molecule drug discovery and scientific
computing. This person will actively provide computational support for
various drug discovery projects at different stages independently or under
limited supervision. In... 阅读全帖 |
|
r*****4
发帖数: 42 | 4 【 以下文字转载自 Chemistry 讨论区 】
发信人: rice444 (rice), 信区: Chemistry
标 题: 谁能介绍一下 hengrui pharmaceutical
发信站: BBS 未名空间站 (Mon Jan 14 19:20:09 2008)
最近似乎很火 |
|
i*******9
发帖数: 16 | 5 Jiangsu Hengrui Medicine （恒瑞医药） is a leading innovative pharmaceutical
company in China with annual sales of 4.55 billion Chinese Yuan in 2011 and
is poised to continue its growth in coming years. Under the leadership of
successful and experienced scientists and drug discovery veterans returning
from US/Europe, its R&D force now has over 800 scientists and has developed
the most robust innovative drug discovery pipeline in Chinese pharmaceutical
industry.
Hengrui’s R&D engine, Shanghai Hengrui （... 阅读全帖 |
|
i*******9
发帖数: 16 | 6 Jiangsu Hengrui Medicine （恒瑞医药） is a leading innovative pharmaceutical
company in China with annual sales of 4.55 billion Chinese Yuan in 2011 and
is poised to continue its growth in coming years. Under the leadership of
successful and experienced scientists and drug discovery veterans returning
from US/Europe, its R&D force now has over 800 scientists and has developed
the most robust innovative drug discovery pipeline in Chinese pharmaceutical
industry.
Hengrui’s R&D engine, Shanghai Hengrui （... 阅读全帖 |
|
b*******s
发帖数: 5216 | 7 【 以下文字转载自 Returnee 讨论区 】
发信人: KingOfLunHui (轮回之王), 信区: Returnee
标 题: 恒瑞医药上海研究中心诚聘 (转载)
发信站: BBS 未名空间站 (Wed Oct 9 19:41:31 2013, 美东)
发信人: infiniti9 (helix), 信区: Pharmaceutical
标 题: 恒瑞医药上海研究中心诚聘
发信站: BBS 未名空间站 (Wed Jul 11 18:35:45 2012, 美东)
Jiangsu Hengrui Medicine （恒瑞医药） is a leading innovative pharmaceutical
company in China with annual sales of 4.55 billion Chinese Yuan in 2011 and
is poised to continue its growth in coming years. Under the leadership of
successful and experienced scientists... 阅读全帖 |
|
t***h
发帖数: 5601 | 8 Lilly scientists stole $55 million in trade secrets, indictment alleges
J.K. Wall
October 8, 2013
Three former employees of Eli Lilly and Co. allegedly transferred trade
secrets that Lilly values at more than $55 million to a competing Chinese
drug company, according to an indictment unsealed Tuesday in federal court.
The indictment charges two Carmel residents, Guoqing Cao and Shuyu Li, with
seven counts of theft and conspiracy to commit theft. It also describes the
actions of a third man, refe... 阅读全帖 |
|
m****s
发帖数: 18160 | 9 【 以下文字转载自 Pharmaceutical 讨论区 】
发信人: addModules (Apache), 信区: Pharmaceutical
标 题: 诚聘 Computational Chemist for a leading Chinese Pharmaceutical Company (上海)
关键字: 招聘 上海
发信站: BBS 未名空间站 (Mon Jul 8 02:42:08 2013, 美东)
We have an open position in the Computational Chemistry group in the R & D
center at Shanghai Hengrui Pharmaceutical Inc. This person will actively
provide computational support for various drug discovery projects at
different stages independently or under limited supervision. In addit... 阅读全帖 |
|
S*****a
发帖数: 63 | 10 【 以下文字转载自 Pharmaceutical 讨论区 】
发信人: Somalia (Anti-Pirates), 信区: Pharmaceutical
标 题: [转发] Multiple Group Leader positions in Shanghai
发信站: BBS 未名空间站 (Sat May 30 17:36:13 2015, 美东)
Multiple Group Leader positions are available at Shanghai HengRui
Pharmaceuticals Co., Ltd.
HengRui is expanding its R&D center in Shanghai. We're seeking talented
scientists to lead BioPharmaceutical research teams.
PhDs with strong Molecular Biology, Biochemistry, Oncology, Immunology, or
Antibody Engineering backgr... 阅读全帖 |
|
m*****l
发帖数: 28 | 11 Shanghai Hengrui Pharmaceuticals Co., Ltd http://www.shhrp.com (China) is now seeking highly motivated professionals to fill the following positions.
Group leader(s), Principle Scientists in stem cell clinical product R&D
Responsibility:
The main responsibility is to develop stem cell products for clinical
purpose. You will lead a group of scientists (2+) and focus on platform set
up for stem cell isolation、characterization and differentiation;
preclinical standard set up for stem cell product... 阅读全帖 |
|
S*****a
发帖数: 63 | 12 【 以下文字转载自 Pharmaceutical 讨论区 】
发信人: Somalia (Anti-Pirates), 信区: Pharmaceutical
标 题: [转发] Multiple Group Leader positions in Shanghai
发信站: BBS 未名空间站 (Sat May 30 17:36:13 2015, 美东)
Multiple Group Leader positions are available at Shanghai HengRui
Pharmaceuticals Co., Ltd.
HengRui is expanding its R&D center in Shanghai. We're seeking talented
scientists to lead BioPharmaceutical research teams.
PhDs with strong Molecular Biology, Biochemistry, or Immunology background
are encouraged to apply.
Ple... 阅读全帖 |
|
a********s
发帖数: 1 | 13 We have an open position in the Computational Chemistry group in the R & D
center at Shanghai Hengrui Pharmaceutical Inc. This person will actively
provide computational support for various drug discovery projects at
different stages independently or under limited supervision. In addition, he
/she should be an active contributor to the advancement of the key
technologies within the organization, and share computational expertise
within the organization.
Requirements:
We are looking for a computa... 阅读全帖 |
|
m*******s
发帖数: 469 | 14 又一起窃取机密 泄密案件
来源: lilipp 于 2013-10-09 17:21:46 [档案] [博客] [旧帖] [给我悄悄话] 本文已
被阅读：571次 字体：调大/调小/重置 | 加入书签 | 打印 | 所有跟帖 | 加跟贴 |
查看当前最热讨论主题
证券时报网（www.stcn.com）10月09日讯
根据美国媒体wishtv 10月8日的报道，联邦法庭周二晚些时候的公开文件显示，两位前
礼来科学家被指控泄露5500万美元的商业秘密给其直接竞争对手中国江苏恒瑞医药制药
公司。
报道称，Guoqing Cao和Shuyu Li于8月14日被起诉，两位均出生于中国，但几年前成为
美国公民。根据法庭文件，曹和李居住在卡梅尔时，将有关糖尿病、心脏病和癌症药物
发展专有信息的商业机密复制到外部硬盘。公诉人指控说，两人之间以及另一位未被起
诉的礼来前雇员曾多次互通涉及商业机密的邮件，而这位雇员现任恒瑞医药代表，在起
诉书中并未指名道姓。
美国地方法院法官Mark Dinsmore周二晚裁定，两人应关押在马里恩县监狱直到受审，
并不得保释。检察官寻求这样的裁决是认为这两人如果被释放，有... 阅读全帖 |
|
S*****a
发帖数: 63 | 15 Multiple Group Leader positions are available at Shanghai HengRui
Pharmaceuticals Co., Ltd.
HengRui is expanding its R&D center in Shanghai. We're seeking talented
scientists to lead BioPharmaceutical research teams.
PhDs with strong Molecular Biology, Biochemistry, Oncology, Immunology, or
Antibody Engineering background
are encouraged to apply.
Please send CV to [email protected]
/* */
恒瑞医药成为首家进入“千亿俱乐部”的A股医药上市公司
在股市热火朝天的当下，医药股近期表现突出，而今天A股医药上市公司中，更是诞生
了首家市值过千亿的公司。截止5月27日收盘，恒瑞医药股价上涨5.19%，... 阅读全帖 |
|
m*******s
发帖数: 469 | 16 【 以下文字转载自 Pharmaceutical 讨论区 】
发信人: mitguests (未名过客), 信区: Pharmaceutical
标 题: 两位Eli Lilly中国科学家被指控泄露5500万美元的商业秘密给中国
发信站: BBS 未名空间站 (Thu Oct 10 13:20:43 2013, 美东)
又一起窃取机密 泄密案件
来源: lilipp 于 2013-10-09 17:21:46 [档案] [博客] [旧帖] [给我悄悄话] 本文已
被阅读：571次 字体：调大/调小/重置 | 加入书签 | 打印 | 所有跟帖 | 加跟贴 |
查看当前最热讨论主题
证券时报网（www.stcn.com）10月09日讯
根据美国媒体wishtv 10月8日的报道，联邦法庭周二晚些时候的公开文件显示，两位前
礼来科学家被指控泄露5500万美元的商业秘密给其直接竞争对手中国江苏恒瑞医药制药
公司。
报道称，Guoqing Cao和Shuyu Li于8月14日被起诉，两位均出生于中国，但几年前成为
美国公民。根据法庭文件，曹和李居住在卡梅尔时，将有关糖尿病、心脏病和癌症药物
发... 阅读全帖 |
|
N*********L
发帖数: 517 | 17 组织状况：
目前NIU组织运行良好，网站继续向广大会员公布组织信息，财务保证向每一位提供
email信息的捐款人发出感谢信。截止2009年12月31日，NIU共收到捐款$7827, 扣除各
项费用后结余为$4386.12，其中用于EB-3项目结余为$2674.75。
各项目进展状况：
1. EB-2 剩余名额
EB-2 group由三人（Crystal(iceicer), Jingran Sun, Ming Shao）起草，已于上月向
奥本海姆寄出第一封函件并收到回函。基于中国未拿到7%名额，因此不应该作为
oversubscribed的国家对待的理由，EB-2 group于上周五寄出第二封信要求进一步解释
。下月计划将根据收到的回信起草一份文件，可能发动各地会员拜访议员以施加压力，
或要求奥本海姆与组织直接面谈。另EB-2 group于2010年1月10日下午进行了电话会议
。执行主席Chen Ma主持了此次会议。
2. 提早递交485
执行主席Hengrui Qu在Ming Shao的帮助下起草了一封petition letter, 并于1月7日寄
往国土安全部负责人M |
|
s*****r
发帖数: 11545 | 18 Patent infringement includes statutory damage and actual damage. Statutory
damage is nothing to a company like hengrui, actual damage is hard to prove,
besides, how can lili enforce it against a foreign company?
what lili does is just to create a deterrence effect on its employees. or to
boost the confidence of investors, making it look like that it does have
something valuable in small molecular section. actually. that section should
be shutdown completely. It is full of crap. |
|
t*****9
发帖数: 10416 | 19 According to the indictment, Cao and Li, e-mailed sensitive information
about nine experimental drug research programs at Lilly to Individual #1,
who is employed by Jiangsu Hengrui Medicine Co. Ltd., based in China. |
|
t*****9
发帖数: 10416 | 20 The indictment says the two scientists transferred the Lilly trade secrets
electronically. In one case, Li sent Lilly PowerPoint presentations that
divulged three trade secrets to Cao at Jiangsu Hengrui. |
|
发帖数: 1 | 21 3 月11日 富豪们，为了你们的生命和财富，捐款吧！
刚才看网上说，歼20入主中国空军，错，大错特错！ 歼20不是入主中国空军，歼20是
入主世界空军！ 我说过，这是一场世纪之战，但不应该是国家与国家，种族与种族之
间的战争，而是信仰，不同路线之争。
大家都知道这个Hurun 财富榜，其实这是个掠夺财富，权利的集团。而且如果我没有猜
错的话，不管其原始创立人是谁，现在这个集团已经完全被日本人所操控。刚刚发布的
女性亿万富翁榜，就是他们最新的目标，打击对象。这个网单独把中国，印度富豪列举
出来，说明对中国，印度富豪的打击屠杀最有针对性。 而其实，所有这个富豪榜上的
人都具有潜在危险，只不过时间早晚的问题。因为我的出现，而我又是女的，日本人就
仇恨其所有富豪女性，尤其是中国女性成为首要掠夺对象。如果我没有猜错的话，老干
妈很可能已经落入这个集团之手。最新针对的是排名最高的陈丽华，象Panda Express
，我在想，很可能已经落入他们集团之手。当然，所有在这个名单上的人都有危险，不
在这个名单，在其他名单上也有危险。
前天我打印了一些资料，然后夜里他们潜入我的房间偷走了一部分，或者说... 阅读全帖 |
|
i****d
发帖数: 203 | 22 去年中国药企获美国FDA认证的仿制药品种增加近一倍。企业认为进军美国市场既能提
振营收，也有助于向中国患者证明产品质量.中国制药公司正加大力度打入美国仿制药
市场，去年中国药企获批的仿制药品种增加近一倍。
2017年，中国药企共有38款仿制药（专利已过期、其他药企可以仿制的较低价药品）获
得了美国食品药品管理局(FDA)的批准，而上一年这个数字为22款。本月，市值350亿美
元的中国最大药企江苏恒瑞医药(Jiangsu Hengrui Medicine)凭借其仿制麻醉剂地氟烷
(desflurane)，成为最新一家获FDA认证的中国药企。
中国药企获FDA批准的仿制药与印度相比还较少——印度是世界最大的仿制药出口国，
2016年海外销售额达到164亿美元——去年在美国获批的927款仿制药中，印度占300款
。首款获美国批准的中国产仿制药是在2007年获批的，这比印度晚了10年。
传统上，中国制药公司制造的低成本仿制药供应国内市场。但中国药企认为，把产品投
放美国市场是一条提升收入、并向更信任进口药的中国患者证明其产品质量的途径。美
国是世界最大的仿制药市场，2015年市场规模达到114... 阅读全帖 |
|
T*******5
发帖数: 2 | 23 A Group Leader/Principle Scientist position in Antibody Drug Discovery is
available at Shanghai Hengrui Pharmaceuticals Co. Ltd.
Responsibility:
- Design and perform research to advance cancer immunotherapy drug discovery
programs. Provide hands-on experimental support.
- Develop and perform in vitro immunoassays including primary lymphocyte
cultures, tumor-lymphocyte co-cultures, etc.
- Establish and run ex vivo tumor models.
- Stay abreast of latest scientific and technology advancements in t... 阅读全帖 |
|
N*********L
发帖数: 517 | 24 各项目进展状况：
1. 华盛顿请愿游行活动
进展由项目组另行安排公布
2. 提早递交485
项目主席Hengrui Qu给国土安全部的直接负责人发信，电话，email都没有回音。准备
通过拜访议员的时候提出此事。 感谢网友JWE, JWE提供了其上司Denise Vanison (New Chief, Office of Policy and Strategy, USCIS)的联系方式, 三月份将主要联系此人.
3. EB-2剩余名额
项目主席Chen Ma介绍目前由于志愿者人手少，议员跟进比较困难。与奥本海姆的直接
接触已由Chunsheng Yang开始启动。NIU打算再给奥本海姆写一封信，知会其游行事项
。另外由于人手不足，全国范围内议员campaign可能效果不好，将考虑重点针对二十个
移民委员会的议员。目前这二十个议员中，只有三个在联系跟进。项目主席Chen Ma会
负责与众议院移民委员会的会长联系。NIU再次呼吁广大热心志愿者能够积极参与。
http://bbs.niunational.org/viewtopic.php?f=8&t=1516&p=2505 |
|
N*********L
发帖数: 517 | 25 组织状况：
目前NIU组织运行良好，网站继续向广大会员公布组织信息，财务保证向每一位提供
email信息的捐款人发出感谢信。截止2009年12月31日，NIU共收到捐款$7827, 扣除各
项费用后结余为$4386.12，其中用于EB-3项目结余为$2674.75。
各项目进展状况：
1. EB-2 剩余名额
EB-2 group由三人（Crystal(iceicer), Jingran Sun, Ming Shao）起草，已于上月向
奥本海姆寄出第一封函件并收到回函。基于中国未拿到7%名额，因此不应该作为
oversubscribed的国家对待的理由，EB-2 group于上周五寄出第二封信要求进一步解释
。下月计划将根据收到的回信起草一份文件，可能发动各地会员拜访议员以施加压力，
或要求奥本海姆与组织直接面谈。另EB-2 group于2010年1月10日下午进行了电话会议
。执行主席Chen Ma主持了此次会议。
2. 提早递交485
执行主席Hengrui Qu在Ming Shao的帮助下起草了一封petition letter, 并于1月7日寄
往国土安全部负责人M |
|
N*********L
发帖数: 517 | 26 组织状况：
目前NIU组织运行良好，网站继续向广大会员公布组织信息，财务保证向每一位提供
email信息的捐款人发出感谢信。截止2009年12月31日，NIU共收到捐款$7827, 扣除各
项费用后结余为$4386.12，其中用于EB-3项目结余为$2674.75。
各项目进展状况：
1. EB-2 剩余名额
EB-2 group由三人（Crystal(iceicer), Jingran Sun, Ming Shao）起草，已于上月向
奥本海姆寄出第一封函件并收到回函。基于中国未拿到7%名额，因此不应该作为
oversubscribed的国家对待的理由，EB-2 group于上周五寄出第二封信要求进一步解释
。下月计划将根据收到的回信起草一份文件，可能发动各地会员拜访议员以施加压力，
或要求奥本海姆与组织直接面谈。另EB-2 group于2010年1月10日下午进行了电话会议
。执行主席Chen Ma主持了此次会议。
2. 提早递交485
执行主席Hengrui Qu在Ming Shao的帮助下起草了一封petition letter, 并于1月7日寄
往国土安全部负责人M |
|
N*********L
发帖数: 517 | 27 组织状况：
目前NIU组织运行良好，网站继续向广大会员公布组织信息，财务保证向每一位提供
email信息的捐款人发出感谢信。截止2009年12月31日，NIU共收到捐款$7827, 扣除各
项费用后结余为$4386.12，其中用于EB-3项目结余为$2674.75。
各项目进展状况：
1. EB-2 剩余名额
EB-2 group由三人（Crystal(iceicer), Jingran Sun, Ming Shao）起草，已于上月向
奥本海姆寄出第一封函件并收到回函。基于中国未拿到7%名额，因此不应该作为
oversubscribed的国家对待的理由，EB-2 group于上周五寄出第二封信要求进一步解释
。下月计划将根据收到的回信起草一份文件，可能发动各地会员拜访议员以施加压力，
或要求奥本海姆与组织直接面谈。另EB-2 group于2010年1月10日下午进行了电话会议
。执行主席Chen Ma主持了此次会议。
2. 提早递交485
执行主席Hengrui Qu在Ming Shao的帮助下起草了一封petition letter, 并于1月7日寄
往国土安全部负责人M |
|
Q********8
发帖数: 3 | 28 yiyi2005 = cnus = p8388 = FA8 = NIU前主席 Qu Hengrui。在任NIU主席期间，他以
独断专行听不得不同意见著称并骂走了几批志愿者。他在下台后经常用各种马甲在网上
攻击NIU，行为非常令人不齿。
EB23版 - [合集] yiyi2005和cnus
Pumba
2010-06-18 20:06:09
来自: 208.94. 1☆─────────────────────────────────────☆
pplulu (皮皮鲁) 于 (Fri Jun 18 14:20:58 2010, 美东) 提到:
有什么联系吗？p838说话的口气和方式是难以让人舒服，但这俩ID在版上
来来去去说车轱辘话也挺让人烦的。我一打酱油的，不代表任何一方。
☆─────────────────────────────────────☆
e39 (树村板锹) 于 (Fri Jun 18 16:00:34 2010, 美东) 提到:
同意。这个yiyi2005整个一个祥林嫂, 经常自言自语，自己跟自己的贴，建设性的意见
没见有，风凉话和牢骚倒一大堆。
发信人: deliv... 阅读全帖 |
|
g****g
发帖数: 74 | 29 刚查了一下，文章list的foundation 信息
First one
FUNDING:Braun Anaesthesia Scientific Research Fund and Wu Jieping Medical
Foundation, Beijing, China. Study drugs were manufactured and supplied by
Jiangsu Hengrui Medicine Co, Ltd, Jiangsu, China.
second literature
Acknowledgments
We thank all the health professionals who were involved in the CNHSS and the
3B study for their contributions to data collection and quality control.
The CNHSS was supported by a research grant from Novo Nordisk China, and the
3B s... 阅读全帖 |
|
发帖数: 1 | 30 Welcome To Attend The 2nd Annual Conference of Chinese Antibody Society
The Chinese Antibody Society is going to host the Second Annual Conference
with a theme of “Therapeutic Antibodies: Frontiers and Opportunities” on
April 29th, 2018 in Cambridge, MA. The conference will discuss the antibody-
related technological advances, challenges and opportunities in discovery,
development, clinical trials, patent and biosimilar of therapeutic
antibodies as well as the progress of immuno-oncology.
Chines... 阅读全帖 |
|
发帖数: 1 | 31 Welcome To Attend The 2nd Annual Conference of Chinese Antibody Society
The Chinese Antibody Society is going to host the Second Annual Conference
with a theme of “Therapeutic Antibodies: Frontiers and Opportunities” on
April 29th, 2018 in Cambridge, MA. The conference will discuss the antibody-
related technological advances, challenges and opportunities in discovery,
development, clinical trials, patent and biosimilar of therapeutic
antibodies as well as the progress of immuno-oncology.
Chines... 阅读全帖 |
|
T*******5
发帖数: 2 | 32 A Group Leader/Principle Scientist position in Antibody Drug Discovery is
available at Shanghai Hengrui Pharmaceuticals Co. Ltd.
Responsibility:
- Design and perform research to advance cancer immunotherapy drug discovery
programs. Provide hands-on experimental support.
- Develop and perform in vitro immunoassays including primary lymphocyte
cultures, tumor-lymphocyte co-cultures, etc.
- Establish and run ex vivo tumor models.
- Stay abreast of latest scientific and technology advancements in t... 阅读全帖 |
|
发帖数: 1 | 33 Welcome To Attend The 2nd Annual Conference of Chinese Antibody Society
The Chinese Antibody Society is going to host the Second Annual Conference
with a theme of “Therapeutic Antibodies: Frontiers and Opportunities” on
April 29th, 2018 in Cambridge, MA. The conference will discuss the antibody-
related technological advances, challenges and opportunities in discovery,
development, clinical trials, patent and biosimilar of therapeutic
antibodies as well as the progress of immuno-oncology.
Chines... 阅读全帖 |
|
发帖数: 1 | 34 Welcome To Attend The 2nd Annual Conference of Chinese Antibody Society
The Chinese Antibody Society is going to host the Second Annual Conference
with a theme of “Therapeutic Antibodies: Frontiers and Opportunities” on
April 29th, 2018 in Cambridge, MA. The conference will discuss the antibody-
related technological advances, challenges and opportunities in discovery,
development, clinical trials, patent and biosimilar of therapeutic
antibodies as well as the progress of immuno-oncology.
Chines... 阅读全帖 |
|
